Clinical trial
A randomized, double-blind study of capecitabine plus tesetaxel versus capecitabine plus placebo as second-line therapy in subjects with gastric cancer
To evaluate the efficacy and safety of capecitabine plus tesetaxel (capecitabine-tesetaxel) versus capecitabine plus placebo (capecitabine-placebo) as second-line therapy in subjects with gastric cancer
| Category | Value |
|---|---|
| Study start date | 2011-09-08 |